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INHIBITORS OF STAT3 
RELATED APPLICATION 
This application claims priority from U.S. provisional 5 
application Ser. No. 61/097,693, which was filed on 17 Sep. 
2008, and which is incorporated herein by reference in its 
entirety. 
2 
existing chemotherapeutic agents, potentially reducing the 
side effects associated with conventional, aggressive chemo-
therapy. 
Despite the difficulties in identifying protein surface-rec-
ognition agents, the promise of STAT3 modulators warrants 
investigation. Successful peptidic and nonpeptidomimetic 
small molecules that are capable of targeting malignant cell 
lines with constitutively activated Stat3 protein are limited to 
a few examples that include Stattic, STA-21, and S3I-201, 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with government support under 
CAI 06439 and CA128865 awarded by the National Institutes 
10 which were all identified through high-throughput virtual or 
biochemical screening approaches. Our first-generation 
designs were simple peptidomimetics derived from the natu-
ral sequence, of which ISS610 was the most potent (see FIG. 
of Health. The government has certain rights in the invention. 15 
FIELD OF THE INVENTION 
The present invention relates to the field of cellular dys-
function diseases such as cancer and, more particularly, to 20 
diseases characterized by overexpression ofSTAT3 protein. 
BACKGROUND OF THE INVENTION 
1). More recently we have discovered S3I-M2001 (com-
pound 15, Table 1) an oxazole-based small-molecule inhibi-
tor that shows promising inhibition of Stat3 function, and we 
herein report a family of rationally designed small-molecule, 
nonpeptidic Stat3 inhibitors. 
These agents inhibit Stat3 protein dimerization and induce 
apoptosis in Stat3-transformed cells and Stat3-dependent 
breast oncogenic cell lines. The crystal structure of the Stat3-
SH2 domain reveals a shallow triangular pocket that is com-
posed of two hydrophobic sites and a hydrophilic phosphate-
recognition pocket. Docking studies on our initial lead, 
STAT3 is the acronym for signal transducer and activator of 
transcription 3. As the name implies, STAT3 is a transcription 
factor and, in humans, it is encoded by the gene appropriately 
known as the STAT3 gene. 
25 peptidomimetic, ISS610, showed that only the hydrophobic 
pockets in the binding domain were effectively occupied (See 
FIG. 1 A). To address this problem we theorized that trisub-
stituted heterocyclic scaffolds, such as oxazoles and thiaz-
oles, might effectively access all three sites (FIG. lB). STAT3 is a protein which belongs in a family of related 
STAT proteins. STAT proteins arephosphorylated in response 30 
to various growth factors and cytokines which are associated 
with cell receptors. The phoshorylated STAT proteins then 
SUMMARY OF THE INVENTION 
form either homo or heterodimers which move into the cell With the foregoing in mind, the present invention discloses 
nucleus to function as transcription activators. Growth factors various small molecule compounds which are inhibitors of 
and cytokines which are known to activate STAT proteins 35 STAT3. Additionally, the invention includes compositions 
include IL5, IL6, LIF, IFNs, EGF and BMP2. containing the disclosed STAT3 inhibitory compounds, as 
STAT3 is known to be responsible for mediating expres- well as methods of treatment employing these compounds 
sion of many genes when the cell is exposed to stimuli. and compositions. 
Accordingly, STAT3 has a central role in important cellular The present investigation sought to rationally develop 
processes involving cell growth and death, apoptosis. 40 small molecule probes derived from the native STAT3 bind-
Presence of constitutive STAT3 is found in a number of ing sequence. Herein reported is the first rational design and 
human cancers and has also been found to be an indicator of synthesis of small molecule STAT3 inhibitors which selec-
poor outcome. Constitutive STAT3 promotes cancerous cell tively inhibit STAT3 protein dimerization and induce apop-
growth by being anti-apoptotic and also stimulating uncon- tosis in STAT3 transformed cells and STAT3-dependent 
trolled cell proliferation. 45 breast and pancreatic oncogenic cell lines. 
Suppression of constitutive STAT3 protein activation in As noted above, the crystal structure of the STAT3-SH2 
human malignancies represents an important target for domain includes a shallow triangular pocket containing two 
molecular therapeutic intervention. STAT proteins mediate hydrophobic sites and a hydrophilic phosphate-recognition 
the relay of extracellular signals from various cell surface pocket. Docking studies of the initial lead compound, pepti-
protein receptors to the nucleus, where they help to initiate 50 domimetic ISS610, indicated that only the hydrophobic 
and regulate specific anti-apoptotic and cell survival gene pockets in the binding domain were effectively occupied (See 
expression. In part cular, the S TAT3 protein isoform is known FIG. lA). Therefore, it was theorized that perhaps trisubsti-
to directly up-regulate Bel-XL, c-Myc, Mel-I, VEGF and tuted heterocyclic scaffolds, such as oxazoles and thiazoles, 
cyclin DI/D2, contributing directly to compromised cellular might effectively access all three sites (FIG. lB). Flexible 
regulation by stimulating cell proliferation and preventing 55 ligand-docking studies (GOLD) directed the design and 
apoptosis in numerous human cancers. assembly of oxazole and thiazole scaffolds. The compounds 
STAT3 activation occurs via phosphorylation of tyrosine of the present invention were prepared as outlined in the 
705, which promotes STAT dimerformation through recipro- scheme shown in FIG. 2 and below; the thiazole derivatives 
cal STAT phosphotyrosine-SH2 domain interactions." STAT were synthesized via traditional hantzsch synthetic protocols. 
dimers then translocate to the nucleus, where they regulate 60 General Procedure A (Alkylation ofN-(Diphenylmethyl-
unique gene expression programs through interaction with ene)glycine ethyl ester): To a flame dried three necked flask 
specific DNA response elements. STAT3 targeted gene under nitrogen and fitted with an over head mechanical stirrer 
expression confers resistance to apoptosis in many tumor was added N-(Diphenylmethylene)glycine ethyl ester (1 eq) 
cells. and promotes cell survival, contributing to the resis- and THF (2 mL/mmol). The resulting solution was cooled to 
tance of these cancers to currently available chemotherapeu- 65 - 78° C., and LiHMDS (1.0 M, 1.1 eq) was added. A thick 
tics. Successful STAT3 inhibitors may thus be used to sensi- yellow precipitate forms slowly over 4 hours, at which time a 
tize human cancers with constitutively active STAT3 to solution of the required acid chloride (1.0 eq) in THF (1 
US 8,969,578 B2 
3 
mL/mmol) is added dropwise over 1 hour. After complete 
addition of the acid chloride, the resulting solution was 
allowed to warm slowly to room temperature over night, and 
then the reaction was quenched with 2M HCl (1 mL/mmol). 
The resulting solution was washed twice with EtOAc (1 5 
mL/mmol), and the aqueous layer evaporated to dryness. The 
resulting solid was dissolved in methanol (0.5 mL/mmol), 
and an equal amount EtOAc added to induce complete pre-
cipitation of inorganic salts, which were then removed by 
filtration. The resulting solution was reduced to dryness, and 10 
the product used without further purification. 
General Procedure B (Amide formation from Acids): The 
required acid (1.0 eq) was added in one portion to a solution 
ofHBTU (1.1 eq) andDIPEA (3.0 eq) inDMF (1 mL/mmol), 
and the resulting solution stirred at room temperature for 10 15 
minutes. The required amine was then dissolved in a solution 
of DIPEA (2.0 eq) in DMF (1 mL/mmol) and added to the 
activated acid in one portion. The resulting solution was 
stirred for 4 hours, then diluted with EtOAc (10 mL/mmol) 
and washed successively with equal volumes of: brine, 2M 20 
HCl, saturated bicarbonate and brine. The organic layer was 
dried over magnesium sulfate, and the solvent was removed 
under reduced pressure to afford the desired amide. 
4 
di-tert-butyl diisopropylphosphoramidate (1.5 eq) was added 
in one portion. The resulting solution was stirred at room 
temperature over night, then cooled in an ice bath and then 
m-CPBA (1.1 eq) was added in small portions. The resulting 
solution was extracted into EtOAc (20 mL/mmol), and 
washed successively with IM HCl, saturated sodium bicar-
bonate, and brine. The organic phase was dried over magne-
sium sulfate, and the solvent was removed under reduced 
pressure. 
General Procedure H (tButyl ester TFA mediated depro-
tection): To a stirred solution of tert-butyl ester (1 eq) in 
CH2Cl2 (1 mL/mmol) under N2 was added dropwise trifluo-
roacetic acid (100 equiv) and allowed to stir at room tempera-
ture for 3 hrs. The reaction was monitored via TLC and 
stopped upon consumption of starting material. The solution 
was concentrated and purified via silica gel chromatography 
to yield pure carboxylic acid. 
General Procedure I involved the hydrogenolysis ofbenzyl 
protected phosphate esters, illustrated in the synthetic scheme 
shown in FIG. 2, as would be known by those skilled in the art. 
Synthesis of Oxazole Rl =Phenyl Derivatives. 
Phosphoric acid mono-[ 4-( 4-hexylcarbamoyl-2-phenyl-
oxazol-5-ylmethyl}-phenyl]ester (PGB2-107) (12aa, 
Rl=phenyl, R2=hexyl); Reaction of llaa according to pro-
cedure I, yield after rpHPLC (78%). lH NMR (MeOD)™ 
0.83 (3H, t, 1=6.7 Hz, CH3), 1.25-1.34 (SH, m, CH2), 1.50-
1.60 (2H, m, CH2), 3.30 (2H, t, J=7.3 Hz, CH2), 4.37 (2H, s, 
CH2), 7.06 (2H, d, J=S.4 Hz,Ar-H), 7.23 (2H, d, J=S.4 Hz, 
Ar-H), 7.39 (4H, dd, J=5.1and1.8 Hz,Ar-H), 7.90 (lH, 
m, Ar-H); 13C NMR (MeOD)™ 14.7, 24.0, 28.1, 31.1, 
32.2, 33.1, 40.5, 116.2, 122.1, 127.8, 129.1, 130.4, 130.6, 
130.9, 137.0, 137.9, 151.2, 154.7, 168.2; HRMS (TOF MS-
ES), calcd. for C23H28N206P [M+H] m/z=459.1667, fnd. 
459.1658; rpHPLC tR: condition (I) 17.106 (II) 15.995 min-
General Procedure C (Oxazole formation): Iodine (1.1 eq) 
was added to a solution of triphenylphosphine (1.1 eq) dis- 25 
solved in DCM (20 mL/mmol) in a flame dried flask under 
nitrogen, and the resulting yellow solution stirred for 5 min-
utes. TEA (2.2 eq) was then added and the solution stirred 
under nitrogen for a further 5 minutes. The required amide 
(1.0 eq) was dissolved in DCM (10 mL/mmol) and added 30 
dropwise over 10 minutes to the solution of triphenylphos-
phine diiodide. After stirring for 4 hours excess tirphe-
nylphosphine diiodide was quenched by addition of MeOH 
(5.0 eq), and the resulting solution absorbed directly onto 
silica gel, and purified by FCC. 35 utes, purity 95%. 
Phosphoric acid mono-{ 4-[ 4-(3-methoxy-phenylcarbam-
oyl-2-phenyl-oxazol-5-ylmethyl]-phenyl}ester (PGB2-099) 
(12ab, Rl=phenyl, R2=3-methoxy-aniline); Reaction of 
1 lab according to procedure I, yield after rpHPLC (89% ). lH 
NMR (MeOD)™ 3.80 (3H, s, CH3), 6.68-6.72 (lH, m, 
Ar-H), 7.14 (2H, d, J=S.3 Hz, Ar-H), 7.24 (2H, d, J=5.1 
Hz, Ar-H), 7.35 (2H, d, J=S.3 Hz, Ar-H), 7.42-7.50 (4H, 
m, Ar-H), 8.02 (2H, dd, J=7.4 and 3.4 Hz, Ar-H); 13C 
NMR (MeOD)™ 29.2, 59.2, 101.0, 111.5, 113.4, 119.4, 
General Procedure D (Base Ester Hydrolysis): An aqueous 
solution of sodium hydroxide (2M, 3 eq) was added to a 
solution of the required ester (1 eq) dissolved in 1:1 THF/ 
Water (40 mL/mmol). The resulting solution was stirred at 
room temperature over night, and the pH raised to - 7 by 40 
addition of 2M HCI. The reaction was extracted into EtOAc 
(100 mL/mmol), and washed with brine (20 mL/mmol). The 
organic phase was dried over magnesium sulfate, and solvent 
removed under reduced pressure to afford the desired car-
boxylic acid. 45 119.5, 122.2, 125.3, 125.32, 128.1, 128.2, 128.23, 130.1, 
130.2, 135.4, 135.42, 138.4, 139.1, 139.5, 140.1, 152.1, 
156.7, 163.1, 164.0; HRMS (TOF MS-ES), calcd. for 
C24H22N207P [M+H] m/z=481.1158, fnd. 481.1165; 
General Procedure E (tert-butylation of carboxylic acid). 
The suitable carboxylic acid (1 equiv) was dissolved in 
CH2Cl2 (10 ml/mmol), to which tert-Butyl 3,3,3-trichloro-
acetamide (2 equiv) was added in a solution of cyclohexane (2 
ml/mmol) followed by the addition of BF3.etherate (20 50 
µl/mmol). The reaction solution was then stirred at room 
temperature under an N2 atmosphere for 2 hrs. The reaction 
was monitored by TLC, until all the starting material had been 
consumed. 
General Procedure F (Hydrogenolysis of benzyl ether): 55 
The required benzyl protected phenol (1 equiv) was dissolved 
in a stirred solution ofMeOH:EtOAc (1: 1 ). The solution was 
then degassed thoroughly before the addition of Pd/C 10% 
(10 mg/mmol). H2 gas was then bubbled through the solution 
for 5 mins before the solution was put under an atmosphere of 60 
H2 gas and stirred continuously for 3 hrs. The hydrogen gas 
was excluded from the reaction vessel and the reaction mix-
ture filtered to remove the Pd/C through glass fibre paper. The 
solution was then concentrated to give pure product. 
General Procedure G (Phosphorylation with Phosphorami- 65 
date): The required phenol (1 equiv) was dissolvedinDMF (1 
mL/mmol), 3% w/w tetratrazole in acetonitrile (4 eq), and 
rpHPLC tR: condition (I) 12.287 minutes, purity 99%. 
Phosphoric acid mono-{ 4-[ 4-( 4-cyclohexyl-phenylcar-
bamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl}ester (PGB2-
105) (12ac, Rl=phenyl, R2=4-cyclohexyl-aniline); Reaction 
ofl lac according to procedure I, yield after rpHPLC (84%). 
lHNMR(MeOD)™ 1.85-2.50 (!OH, m, CH2), 3.17 (lH, m, 
CH), 5.13 (2H, s, CH2), 7.78 (2H, d, J=S.4 Hz, Ar-H), 7.85 
(2H, d, J=S.4 Hz, Ar-H), 8.14 (3H, m, Ar-H), 8.25 (2H, d, 
J=S.5 Hz, Ar-H), 8.65 (2H, dd, J=5.8 and 1.9 Hz, Ar-H); 
13C NMR (MeOD)™ 27.2, 28.0, 32.0, 35.7, 45.5, 121.7, 
121.78, 122.0, 127.5, 127.8, 128.2, 130.1, 131.0, 131.0, 
131.7, 132.2, 134.5, 136.7, 145.9, 156.8, 160.8, 161.7; 
HRMS (TOF MS-ES), calcd. for C29H30N206P [M+H] 
m/z=533.1849, fnd. 533.1842; rpHPLC tR: condition (I) 
16.137 (III) 16.480 minutes, purity 99%. 
Phosphoric acid mono-{ 4-[ 4-( 4-bromo-phenylcarbam-
oyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl }ester (PGB2-
097) (12ad, Rl=phenyl, R2=4-bromo-aniline); Reaction of 
1 lad according to procedure I, yield after rpHPLC (79% ). lH 
US 8,969,578 B2 
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NMR (MeOD)™ 4.52 (2H, s, CH2), 7.14-7.20 (3H, m, 
Ar-H), 7.18 (2H, d, 1=8.5 Hz,Ar-H), 7.38 (4H, dd, 1=13.5 
and 6.0 Hz, Ar-H), 7.48-7 .52 (2H, m, Ar-H), 7 .88 (2H, d, 
1=7.8 Hz, Ar-H), 8.04 (2H, d, 1=7.8 and 4.0 Hz, Ar-H); 
13C NMR (MeOD)™ 32.0, 121.7, 121.9, 125.7, 127.6, 5 
127.8, 129.9, 130.1, 131.0, 131.7, 132.2, 134.4, 139.1, 152.1, 
157.0, 160.8, 161.8; HRMS;rpHPLCtR: condition(!) 10.970 
(II) 8.266 minutes, purity 99%. 
Phosphoric acid mono-{ 4-[ 4-(3-bromo-phenylcarbam-
oyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl }ester (PGB2- 10 
139) (12ae, Rl=phenyl, R2=3-bromo-aniline); Reaction of 
1 lae according to procedure I, yield after rpHPLC (83% ). lH 
NMR (MeOD)™ 4.50 (2H, s, CH2), 7.15 (lH, d, 1=7.4 Hz, 
Ar-H), 7.18 (2H, d, 1=8.5 Hz, Ar-H), 7.34 (2H, d, 1=8.5 
Hz, Ar-H), 7.38 (lH, t, 1=8.5 Hz, Ar-H), 7.51 (3H, m, 15 
Ar-H), 7.74 (2H, d, 1=8.6 Hz, Ar-H), 8.05 (2H, dd, 1=5.4 
and 1.8 Hz, Ar-H); 13C NMR (MeOD)™ 32.4, 115.9, 
118.7, 122.2, 122.24, 122.3, 125.0, 126.0, 127.9, 130.3, 
130.4, 131.0, 132.5, 136.9, 137.5, 137.9, 149.8, 157.7, 150.9, 
165.7; rpHPLC tR: condition (I) 15.682 (II) 14.019 minutes, 20 
purity 98%. 
Synthesis of Oxazole Rl =Naphthyl Derivatives. 
Phosphoric acid mono-[ 4-( 4-hexylcarbamoyl-2-naphtha-
len-1-yl-oxazol-5-ylmethyl)-phenyl]ester (PGB2-227) 
(12ca, where Rl =naphthyl, R2=hexyl); Reaction of l lca 25 
according to procedure I, yield after rpHPLC (74%). lH 
NMR (MeOD)™0.89 (3H, t, 1=6.9 Hz, CH3), 1.23-1.44 (6H, 
m, CH2), 1.59-1.68 (2H, m, CH2), 3.39 (2H, t, 1=7.3 Hz, 
CH2), 4.50 (2H, s, CH2), 7.13 (2H, d, 1=8.5 Hz,Ar-H), 7.37 
(2H, d, 1=8.5 Hz, Ar-H), 7.50-7.64 (3H, m, Ar-H), 7.90 30 
(lH, d, 1=8.1 Hz, Ar-H), 7.99 (lH, d, 1=8.1 Hz, Ar-H), 
8.09 (lH, d, 1=7.3 Hz, Ar-H), 9.13 (lH, d, 1=8.6 Hz, NH); 
13CNMR(MeOD)™ 14.7, 24.1, 28.2, 31.1, 32.3, 33.1, 41.6, 
116.3 (2xC), 122.1, 125.2, 125.9, 126.5, 127.9 (2xC), 129.1, 
129.6, 130.1, 131.3 (3xC), 133.9, 134.9, 135.8, 151.4, 156.2, 35 
160.3; HRMS (TOF MS-ES+), calcd. for C27H30N06P 
[M+H] m/z=509.1856, fnd. 509.1842; rpHPLC tR: condition 
(I) 13.489 (II) 12.213 minutes, purity 100%. 
6 
(lH, d, 1=8.4 Hz, Ar-H), 10.04 (lH, s, NH); 13C NMR 
(DMSO)™ 25.6, 26.4, 30.5, 34.0, 43.3, 120.3, 121.1, 122.3, 
125.2, 126.0, 126.6, 126.63, 127.9, 128.2, 129.2, 129.4, 
130.5, 131.8, 133.5, 135.9, 143.4, 155.1, 158.1, 159.6; 
HRMS (TOF MS-ES+), calcd. for C27H30N06P [M+H] 
m/z=509.1856, fnd. 509.1842; rpHPLC tR: condition (I) 
15.019 (II) 14.914 minutes, purity 93%. 
Synthesis of Thiazole Rl =Phenyl Derivatives 
Phosphoric acid mono-[ 4-( 4-hexylcarbamoyl-2-phenyl-
thiazol-5-ylmethyl)-phenyl]ester (PGB3-139) (23aa, 
Rl =phenyl, R2=hexyl); Reaction of 22aa according to pro-
cedure F, yield after rpHPLC (85%). lH NMR (MeOD)™ 
0.86 (3H, t, 1=6.7 Hz, CH3), 1.25-1.39 (6H, m, CH2), 1.59 
(2H, m, CH2), 3.34 (2H, t, 1=7.2 Hz, CH2), 4.62 (2H, s, CH2), 
7.10 (2H, d, 1=8.2 Hz, Ar-H), 7.27 (2H, d, 1=8.0 Hz, 
Ar-H), 7 .36-7 .39 (3H, m, Ar-H), 7 .87 (2H, dd, 1=6.0 and 
2.4 Hz,Ar-H); 13C NMR (MeOD)™ 14.4, 23.7, 27.8, 30.7, 
32.7, 32.9, 40.3, 121.7, 127.4, 130.1, 130.9, 131.6, 134.2, 
137.7, 144.5, 146.8, 152.3, 164.5, 165.9; HRMS (TOF MS-
ES), calcd. for C24H22N206PS [M+H] m/z=497.0936, fnd. 
497.0958; rpHPLC tR: condition (I) 12.518 (II) 11.103 min-
utes, purity 100%. 
Phosphoric acid mono-{ 4-[ 4-(3-methoxy-phenylcarbam-
oyl)-2-phenyl-thiazol-5-ylmethyl]-phenyl }ester (PGB3-
143) (23ab, Rl =phenyl, R2=3-methoxy aniline); Reaction of 
22ab according to procedure F, yield after rpHPLC (82% ). 1 H 
NMR (MeOD)™ 3.80 (2H, s, CH3), 4.69 (2H, s, CH2), 6.71 
(lH, dt, 1=6.5 and 2.5 Hz, Ar-H), 7.16 (2H, d, 1=8.5 Hz, 
Ar-H), 7.23-7.27 (2H, m, Ar-H), 7.32 (2H, d, 1=8.2 Hz, 
Ar-H), 7.43-7.48 (4H, m, Ar-H), 7.95-7.98 (2H, m, 
Ar-H); HRMS (TOF MS-ES+), calcd. for C24H22N206SP 
[M+H] m/z=497.0936, fnd. 497.0958; rpHPLC tR: condition 
(I) 12.667 minutes, purity 99%. 
Phosphoric acid mono-{ 4-[ 4-( 4-cyclohexyl-phenylcar-
bamoyl)-2-phenyl-thiazol-5-ylmethyl]-phenyl}ester (PGB3-
147) (23ac, Rl =phenyl, R2=4-cyclohexyl phenyl); Reaction 
of22ac according to procedure F, yield after FCC (67%, 33% 
ethyl acetate in hexanes). lH NMR (DMSO)™ 1.19-1.42 
(6H, m, CH2), 1.69 (lH, d, 1=13.5 Hz, CH2), 1.78 (2H, d, 
40 1=8.3 Hz, CH2), 2.52 (lH, m, CH), 4.65 (2H, s, CH2), 7.11 
(2H, s (broad), Ar-H), 7.21 (2H, d, 1=7.4 Hz, Ar-H), 7.29 
(2H, s (broad), Ar-H), 7.49 (2H, s (broad), Ar-H), 7.74 
(2H, d, 1=7.4 Hz,Ar-H), 7.95 (lH, t, 1=6.l Hz,Ar-H), 8.05 
Phosphoric acid mono-{ 4-[ 4-(3-methoxy-phenylcarbam-
oyl)-2-naphthalen-1-yl-oxazol-5-ylmethyl]-phenyl }ester 
(PGB4-091 ); Reaction of l lcb according to procedure I, 
yield after rpHPLC ( 45% ). 1H NMR (MeOD)™ 3.85 (3H, s, 
CH3), 4.61 (2H, s, CH2), 6.76 (lH, td, 1=6.4 and 2.5 Hz, 
Ar-H), 7.21 (2H, d, 1=8.4 Hz, Ar-H), 7.29-7.32 (2H, m, 
Ar-H), 7.45 (2H, d, 1=8.4 Hz, Ar-H), 7.50-7.53 (lH, m, 45 
Ar-H), 7.59 (2H, dd, 1=8.1 and 7.3 Hz, Ar-H), 7.69 (lH, 
ddd, 1=8.5, 6.8 and 1.3 Hz, Ar-H), 7.97 (lH, d, 1=7.8 Hz, 
Ar-H), 8.06 (lH, d, 1=8.2 Hz, Ar-H), 8.17 (lH, dd, 1=7.3 
and 1.0 Hz, Ar-H), 9.12 (lH, dd, 1=8.6 Hz, Ar-H); 13C 
NMR (MeOD)™ 32.4, 56.1, 108.1, 111.8, 114.6, 122.1, 50 
124.5, 126.4, 127.2, 127.9, 129.2, 129.8, 130.1, 131.0, 131.4, 
131.6, 132.0, 133.3, 134.7, 135.8, 140.6, 152.4, 157.3, 161.0, 
162.0, 162.3; HRMS (TOF MS-ES+), calcd. for 
C28H24N07P [M+H] m/z=531.1331, fnd. 531.1321; 
rpHPLC tR: condition (I) 13 .064 (II) 11.925 minutes, purity 55 
100%. 
Phosphoric acid mono-{ 4-[ 4-( 4-cyclohexyl-phenylcar-
bamoyl)-2-naphthalen-1-yl-oxazol-5-ylmethyl]-
phenyl}ester (PGB2-067); Reaction of l lcc according to 
procedure I, yield after rpHPLC (79%). lH NMR (DMSO) 60 
1.20-1.41 (5H, m, CH2), 1.65-1.82 (SH, m, CH2), 2.49, (lH, 
tt, 1=10.1 and2.6 Hz,Ar-H), 4.51 (2H, s, CH2), 7.11 (2H, d, 
1=7.9 Hz, Ar-H), 7.21 (2H, d, 1=8.3 Hz, Ar-H), 7.31 (2H, 
d, 1=7.9 Hz, Ar-H), 7.64 (2H, dd, 1=14.3 and 7.1 Hz, 
Ar-H), 7.70(1H,dd,1=8.1and7.2Hz,Ar-H),7.74(2H,d, 65 
1=8.4 Hz, Ar-H), 8.03 (lH, d, 1=8.4 Hz, Ar-H), 8.13 (lH, 
d, 1=8.1 Hz, Ar-H), 8.18 (lH, d, 1=7.2 Hz, Ar-H), 9.24 
(2H, m,Ar-H), 10.15 (lH, s, NH); HRMS (TOF MS-ES+), 
calcd. for C26H24N04 [M+H] m/z=475.1465, fnd. 
475.1457; rpHPLC tR: condition (I) 16.033, purity 100%. 
Synthesis of Thiazole Rl =Napthyl Derivatives 
Phosphoric acid mono-[ 4-( 4-hexylcarbamoyl)-2-naphtha-
len-1-yl-thiazol-5-ylmethyl]-phenyl }ester (PGB3-291) 
(23bb, Rl=naphthyl, R2=4-methoxy phenyl) (PGB3-291) 
(23ba, Rl=naphthyl, R2=hexyl aniline); 1H NMR (CDC13) 
0.83 (3H, t, 1=6.5 Hz, CH3), 1.24-1.38 (6H, m, CH2), 1.50-
1.51 (2H, m, CH2), 3.36-3.39 (2H, m, CH2), 4.57 (2H, s, 
CH2), 7.04-7.20 (3H, m,Ar-H), 7.38-7.60 (4H,m,Ar-H), 
7.75 (lH, s,Ar-H), 7.84 (2H, t, 1=8.3 Hz,Ar-H), 8.55 (lH, 
d, 1=7.6 Hz, Ar-H); 13C NMR (CDC13) 13.9, 22.5, 26.5, 
29.3, 31.4, 32.0, 39.7, 120.9, 125.0, 125.3, 126.4, 127.3, 
128.4, 128.7, 129.7, 130.2, 130.7, 133.9, 146.5, 149.5, 
155.01, 163.7; HRMS (TOF MS-ES+), calcd. for 
C27H30N205PS [M+H] m/z=525.1596, fnd. 525.1579; 
rpHPLC tR: condition (I) 15 .908, (II) 16.140 minutes, purity 
99%. 
Phosphoric acid mono-{ 4-[ 4-(3-methoxy-phenylcarbam-
oyl)-2-naphthalen-1-yl-thiazol-5-ylmethyl]-phenyl }ester 
(PGB4-003) (23bb, Rl =naphthyl, R2=4-methoxy phenyl); 
lHNMR (CDC13) 3.67 (3H, s, CH3), 4.50 (2H, s, CH2), 6.57 
(lH, d, 1=8.0 Hz, Ar-H), 6.96-7.46 (1 lH, m, Ar-H), 7 .68-
US 8,969,578 B2 
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7.78 (2H, m, Ar-H), 8.50 (lH, d, J=6.7 Hz, Ar-H), 9.34 
(lH, s, NH); 13C NMR (CDC13) 33.1, 56.0, 106.1, 110.9, 
112.8, 125.6, 125.8, 127.1, 128.1, 129.1, 129.3, 130.3, 
8 
and other embodiments of the invention are shown in Table I. 
These compounds may be prepared according to the scheme 
shown in FIG. 2. QQ 
130.35, 130.5, 130.6, 131.5, 134.6, 137.9, 139.5, 150.4, Anothercompoundoftheinventionisonehavingachemi-
153.9, 161.8, 165.0; HRMS (TOF MS-ES+), calcd. for 5 cal structure according to the formula: 
C28H24N206PS [M+H] m/z=547.1091, fnd. 547.1093; 
rpHPLC tR: condition (I) 14.935, (II) 15.048 minutes, purity 
97%. 
Phosphoric acid mono-{ 4-[ 4-( 4-cyclohexyl-phenylcar-
bamoyl)-2-naphthalen-1-yl-thiazol-5-ylmethyl]- 10 
phenyl}ester (PGB4-289) (23bc, Rl =naphthyl, R2=4-cyclo-
hexyl aniline); 1H NMR (CDC13) 1.22-1.39 (SH, m, CH2), 
1.67 (lH, d, J=12.0 Hz, CH), 1.70-1.81 (4H, m, CH2), 2.41 
(lH, t, J=l 1.6 Hz, CH), 4.59 (2H, s, CH2), 6.95-7.17 (6H, m, 
Ar-H), 7.38 (lH, t, J=7.5 Hz, Ar-H), 7.42-7.49 (4H, m, 15 
Ar-H), 7.54 (lH, d, J=7.0Hz,Ar-H), 7.81 (2H, t, J=6.4Hz, whereinX is oxygen, R1 is a phenyl group, R2 is anaphthyl 
Ar-H), 8.56 (lH, d, J=8.2 Hz, Ar-H); 13C NMR (CDC13) amide group and R3 is a phosphate group. 
26.5,27.2,32.7,34.8,44.4, 120.9, 121.3, 125.4, 125.7, 126.8, v h d f h · · h h · 1 
1 et anot er compoun o t e mvent10n as a c em1ca 127.7, 127.8, 128.8, 129.2, 130.3, 130.5, 131.2, 134.3, 135.2, d. h fi l 
20 structure accor mg to t e ormu a: 136.5, 142.8, 145.0, 148.0, 149.8, 161.0, 164.1; HRMS (TOF 
MS-ES+), calcd. for C27H30N205PS [M+H] 
m/z=525.1596, fnd. 525.1613; rpHPLC tR: condition (I) 
13.898, (II) 13.025 minutes, purity 99%. 
Trifluoro-methanesulfonic acid 4-[ 4-( 4-cyclohexyl-phe-
nylcarbamoyl)-2-phenyl-oxazol-5-ylmethyl]-phenyl ester 25 
(PGB3-203) (XX, Rl =phenyl, R2=4-cyclohexyl aniline); 1H 
NMR (CDC13)™ 1.23-1.45 (4H, m, CH2), 1.68-2.93 (6H, m, 
CH2), 2.50 (lH, t, J=l 1.5 and3.0Hz, CH), 4.58 (2H, s, CH2), 
7.21 (2H, d, J=8.4 Hz, Ar-H), 7.23 (2H, d, J=8.4 Hz, 
Ar-H), 7.46-7.53 (4H, m, Ar-H), 7.61 (2H, d, J=8.4 Hz, 30 wherein Xis sulfur, R1 is a phenyl group, 
Ar-H), 8.02 (2H, dd, J=6.55 and3.1Hz,Ar-H),8.86 (lH, 
s, NH); 13C NMR (CDC13)™ 26.0, 26.8, 31.32, 34.5, 43.9, 
120.0, 121.5, 126.4, 126.5, 127.3, 128.9, 130.7, 131.2, 135.1, 
137.3, 144.6, 148.7, 153.9, 159.5; LRMS (MS-ES+), 
m/z=585.1 [M+H]; rpHPLC tR: condition (I) 16.360, (II) 35 
16.375 minutes, purity 99%. 
2-{ 4-[ 4-( 4-Cyclohexyl-phenylcarbamoyl)-2-phenyl-ox-
azol-5-ylmethyl]-phenoxy }-malonic acid (PGB3-213) (XX, 
00 )lN~O/ 
H 
Rl =phenyl, R2=4-cyclohexyl aniline); 1H NMR (CDC13)™ 
1.20-1.48 (5H, m, CH2), 1.68-1.86 (5H, m, CH2), 2.46 (lH, 40 
t, J=8.4 Hz, CH), 4.43 (2H, s, CH2), 5.15 (lH, s, CH), 6.91 and R3 is a phosphate group. 
(2H, d, J=7.3 Hz, Ar-H), 7.18 (2H, d, J=8.4 Hz, Ar-H), Anotherderivativeofthepresentinventionincludesacom-
7 .29 (2H, d, J=7.3 Hz, Ar-H), 7.44-7.47 (3H, m, Ar-H), pound having a chemical structure according to the formula: 
7.57 (2H, d, J=8.4 Hz,Ar-H), 7.99 (2H, t, J=3.7 Hz,Ar-H), 
9.60 (lH, s, NH); 13C NMR (CDC13) 227.3, 28.0, 31.9, 35.8, 45 
45.5, 96.3, 116.6, 122.0, 127.5127.8, 128.2, 130.1, 131.0, 
131.5, 131.7, 132.1, 136.7, 145.9, 157.1, 160.7, 161.8; 
rpHPLC tR: condition (I) 14.347, (II) 13.821 minutes, purity 
95%. 
Accordingly, a first embodiment of the invention is a com- 50 
pound having a generic chemical structure according to the 
following formula: 
55 
60 
wherein Xis oxygen, R 1 is a phenyl group, 
R2 is 
00 )lN~O/ 
H 
wherein X comprises oxygen or sulfur, R 1 comprises a phenyl 
or naphthyl group, R2 comprises an amide group and R3 
comprises a phosphate group. This embodiment of the inven-
tion is a generic molecule which forms the basic structure 
from which the various other embodiments are derived. This 
65 and R
3 is a phosphate group. 
Yet an additional compound included in the invention is 
one having a chemical structure according to the formula: 
US 8,969,578 B2 
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wherein X is sulfur, R 1 is a naphthyl group, 
R2 is 
0 
)lN~ 
H 
and R3 is a phosphate group. 
10 
apparent as the description proceeds when taken in conjunc-
tion with the accompanying drawings, presented for solely 
for exemplary purposes and not with intent to limit the inven-
tion thereto, and in which: 
FIG. lA, according to an embodiment of the present inven-
tion, shows the active site conformation ofISS610, as deter-
mined by flexible ligand docking in the active site of STAT3 
(PDB ID: lBGl) using GOLD 3.0; lead peptidomimetic 
ISS610 displays limited occupation of the active site; expan-
10 sion site indicated by arrow; FIG. lB shows how oxazole 10 
replicates the functionality projection ofISS610 and accesses 
the previously unoccupied region of the SH2 domain 
(red=hydrophobic, blue= hydrophilic); 
FIG. 2 depicts a reaction scheme including the following 
15 conditions: a) R'COOH, HBTU, DIPEA, DMF; b) PPh3 , I2, 
TEA. CH2Cl2; c) 2N NaOH, THF; d) tBu-trichloro aceta-
mide, BF3 (0Et)2; CH2Cl2; e) H2, Pd/C, THF; f) dibenzyldi-
isopropyl phosphoroamidate, tetrazole, mCPBA, CH2Cl2: g) 
Another embodiment of the invention includes a com- 20 
TFA, Et5 SiH, CH2Cl2; h) R2COOH, HBTU, DIPEA, DMF; i) 
H2, Pd/C, EtOAc, HBTU=2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetra methyluronium hexafluorophosphate 
(DIPEA=diisopropylethylamine, DMF=N,N dimethylfor-
mamide, TEA=triethylamine, TFA=trifluoroacetic acid). 
pound having a chemical structure according to the formula: 
wherein Xis oxygen, R 1 is a naphthyl group, 
R2 is 
0 
)lN~ 
H 
and R3 is a phosphate group. 
A further embodiment of the invention is a compound 
having a chemical structure according to the formula: 
wherein X is sulfur, R 1 is a naphthyl group, 
R2 is 
00 )lN~O/ 
H 
and R3 is a phosphate group. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Some of the features, advantages, and benefits of the 
present invention having been stated, others will become 
FIG. 3 shows EMSA data. On the left is EMSA data for in 
25 vitro disruption of STAT23 dimers by compound 10, as 
shown in Table 1; On the right is in vivo disruption of 
NIHJT3/vSrc with compound 10 (100 µM) over 6, 24 and 48 
hour periods; 
FIG. 4 shows a line graph illustrating the dose dependent 
30 effects of compound 10 upon NIH3T3, a mouse breast tissue 
cell line, and NIH3T3/vSrc cell lines using WST-1 mediated 
spectrophotometric analysis; 
FIG. 5 depicts an EC50 determination for compound 19 
induced effects upon pancreatic human cancer cell lines 
35 (pane- I) evaluated using WST-1; and 
FIG. 6 is a line graph illustrating results of a competitive 
binding experiment between the fluorescent probe 5-car-
boxyfluorescein-Gp YLPQTV-NH2 and oxazoles 10, 15, 17 
as well as unlabeled Ac-p YLPQTV-NH2 peptide to STAT3 
40 protein; whereas Ac-pYLPQTV-NH2 displays a 200 nM 
affinity towards STAT3, and oxazole compounds 10, 15, and 
17 do not interact significantly with STAT3. 
DETAILED DESCRIPTION OF THE PREFERRED 
45 EMBODIMENT 
The present invention will now be described more fully 
hereinafter with reference to the accompanying drawings, in 
which preferred embodiments of the invention are shown. 
50 Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which this invention 
pertains. Although methods and materials similar or equiva-
lent to those described herein can be used in the practice or 
55 testing of the present invention, suitable methods and mate-
rials are described below. Any publications, patent applica-
tions, patents, or other references mentioned herein are incor-
porated by reference in their entirety. In case of conflict, the 
present specification, including any definitions, will control. 
60 In addition, the materials, methods and examples given are 
illustrative in nature only and not intended to be limiting. 
Accordingly, this invention may be embodied in many differ-
ent forms and should not be construed as limited to the illus-
trated embodiments set forth herein. Rather, these illustrated 
65 embodiments are provided so that this disclosure will be 
thorough and complete, and will fully convey the scope of the 
invention to those skilled in the art. Other features and advan-
US 8,969,578 B2 
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tages of the invention will be apparent from the following 
detailed description, and from the claims. 
Aspects of the presently disclosed invention were pub-
lished by P. T. Gunning et al., Targeting Protein-Protein Inter-
actions: Suppression ofSTAT3 Dimerization with Rationally 5 
Designed Small-Molecule, Nonpeptidic SH2 Domain Bind-
ers, ChemBioChem 2008, 9, 2800-2803. As noted above, this 
publication is incorporated herein by reference in its entirety. 
The crystal structure of the STAT3-SH2 domain reveals a 
shallow triangular pocket comprising two hydrophobic sites 10 
and a hydrophilic phosphate recognition pocket. Initial pep-
tidomimetic studies failed to identify agents which simulta-
neously projected functionality within all three pockets; see 
FIG. lA. 
12 
oxazole scaffold is able to project substituents in a substan-
tially different orientation than could be achieved with a 
peptide based inhibitor (FIG. 1). 
Five compounds shown in Table 1 displayed IC50 values 
below 100 µM, with oxazole 10 showing significant dimer 
disruption potential (IC50=33 µM). Data suggest limited iso-
form specificity for STAT3 over STAT! protein. 
Dramatic effects were observed though replacement of the 
central core in several cases. Examples of such effects include 
compounds 10 and 11 as shown in Table 1, where the high 
potency displayed by the oxazole analog 10 IC50=33 µM (see 
FIG. 2A.) is severely diminished in the analogous thiazole 11 
(IC50=775 µM). Conversely, thiazole 16 (IC50=25 µM) exhib-
its improvements in activity compared with the correspond-
15 ing oxazole 15 (IC50=58 µM). Molecular modeling studies 
showed that the thiazole scaffolds afforded a functional group 
orientation with higher protein surface complementarity. 
The present investigation was directed to ascertaining 
whether a trisubstituted heterocyclic scaffold could effec-
tively access these three pockets; see FIG. lB. Flexible 
ligand-docking studies (GOLD) directed the design and 
assembly of oxazole and thiazole scaffolds. A series of 
oxazole inhibitors was prepared as outlined in FIG. 2. GOLD 
docking studies predicted a focused set of diversity elements 
deemed suitable for occupation of the SH2 domain. Both R' 
and R2 appendages were predominantly hydrophobic in 
nature to interact with the hydrophobic surface presented by 
residues present in the upper (Phe716, Met660, Pro715) and 25 
lower right (Ser636, Arg595, Lys591) pockets of the STAT3 
active site (FIGS. lA and B). 
Docking studies predict a H-bond between Lys591 and the 
heterocyclic core oxygen or sulfur, which is expected to be 
20 more favorable with harder oxazole oxygen atoms than softer 
thiazole sulfur. In almost all examples, increased potency is 
derived from a thiazole core. 
Control oxazole compound 12, containing the most potent 
arrangement of R 1 and R 2 elements, but lacking a phosphate 
group, was shown to be essentially devoid of activity. Further 
non-phosphorylated scaffolds were prepared and found to be 
impotent STAT3 disruptors. 
Given the extended planar aryl-oxazole construct and the 
propensity of such scaffolds to intercalate with DNA, experi-
ments were conducted to discount potential DNA interaction. 
It was found using fluorescence spectroscopy that DNA-
bound ethidium bromide did not vary upon addition of com-
pound 10, which can thus be considered inert towards DNA. 
Work was undertaken to establish the affinity of the lead 
A screening process evaluated in vitro disruption ofSTAT3 
(dimer)-DNA formation through a previously published 
EMSA based assays, giving a valuable insight into the inhibi- 30 
tor's mode of action against the STAT3 homo-dimer. An 
initial series of STAT3 oxazole and thiazole inhibitors is 
shown in Table 1. Oxazole 7 was prepared as a control agent, 
closely resembling lead peptidomimetic ISS610, to explore 
the efficacy of compounds not projecting sizable appendages 
from the R2 position. STAT3 DNA binding disruption by 
compound 7 was shown to be negligible, presumably due to 
poor inhibitor-protein complementarity. Substitution of 
ISS610 at the acidic terminus had been shown previously to 
decrease potency in all cases studied, suggesting that the 
35 oxazole 10 forthe inactive (unphosphorylated) STAT3 mono-
mer to help determine the mode of action. By using fluores-
cence spectroscopy, K, values were calculated through dis-
placement of an SH2 binding fluorescein-labeled 
GpYLPQTV-NH2 peptide. The most potent inhibitors were 
found to have low affinity with the 
TABLE 1 
IC50 values (µM) for the inhibition ofSTAT3 DNA-binding activity in vitro via oxazole and thiazole analogs of!SS610. 
R2 
~ R3........_0 -<N 
RI 
Compound Scaffold IC50 Values 
Number R1 R2 Core R3 (µM)[aJ 
7 o ... 0 0 P03H2 >1000 _.--lOH 0 
o ... 0 0 P03H2 >1000 ,.--lN~ 0 H 
US 8,969,578 B2 
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TABLE I-continued 
IC50 values (µM) for the inhibition of STAT3 DNA-binding activity in vitro via oxazole and thiazole analogs of!SS610. 
R2 
~ R3'-...0 -(N 
RI 
Compound Scaffold IC50 Values 
Number R1 R2 Core R3 (µM)[aJ 
9 o .... 0 s P03H2 150 ,.--lN~ 0 H 
10 o .... 0 P03H2 33 0 0 
,/lN 
H 
11 o .... s P03H2 775 0 
0 
,/lN 
H 
12 o .... 0 H >1000 0 0 
_,--lN 
H 
13 o .... 00 0 P03H2 90 0 _,-'lN ~ 0/ 
H 
14 o .... 00 s P03H2 28 0 _,--lN ~ 0/ 
H 
15 8··. 0 0 P03H2 58 ,.--lN~ 0 H 
16 8·· .. 0 s P03H2 25 ,/lN~ 0 H 
US 8,969,578 B2 
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TABLE I-continued 
IC50 values (l!Ml for the inhibition of STAT3 DNA-binding activi\y in vitro via oxazole and thiazole analogs of!SS610. 
R2 
~ R3'-...0 -<N 
RI 
Compound 
Number R1 R2 
17 8··. 0 
__ )........_N 
H 
18 8·· .. 0 
__ )........_N 
H 
19 8·· 0 ,0 ,.--lN ~ 0/ H 
where X = 0 or S 
[a]Inhibitor concentration required to decrease STAT3-DNA binding twofold. 
Scaffold IC50 Values 
Core R3 (µM)[aJ 
0 0 P03H2 255 
s 0 P03H2 350 
s 0 P03H2 125 
In addition, cell-based EC50 values were determined for 
potent inhibitors against human breast (MDA-MB-231) can-
cer cell lines (Table 2). Oxazole 10 had the best activity 
against breast cancer (EC50=180 µM) and NIH-3T3/v-src 
unphosphorylated STAT3 monomer (10 and 15, Ki-1 mM; 40 
FIG. 6). These results were attributed to the smaller size of the 
oxazole scaffolds relative to the phosphopeptide, which is 
predicted to make contacts with both the BG and EF loops 
that recognize ligand residues at the pTyr+3 site. Structural 
limitations of the inhibitors might preclude effective interac-
tions with the SH2 domain and reduce their ability to displace 
the extended peptide sequence. 
45 cells (EC50=120 µM) and lacked toxicity for control NIH-
3T3 cells. 
Despite the inherent difficulties associated with the cell 
permeability of phosphate derivatives, promising whole-cell 50 
activities were observed for several lead compounds. Initial in 
vitro whole-cell experiments were conducted against normal 
mouse NIH-3T3 fibroblasts and v-src-transformed counter-
parts (NIH-3T3/v-src) that harbor aberrant STAT3. Inhibitor 
effects upon cell viability, proliferation, and cytotoxicity 55 
were assessed through WST-1, a cell proliferation reagent 
that measures the metabolic activity of viable cells. The most 
potent in vitro inhibitor, compound 10, displayed at least 
ten-fold selectivity toward malignant NIH-3T3/v-src fibro-
blasts with aberrant STAT3 (EC50=120 µM) and negligible 60 
effects toward normal NIH-3T3 fibroblasts, in which STAT3 
pathways are tightly regulated. Conversely, the suppression 
by lead peptidomimetic ISS610 in whole cells required mil-
limolar concentrations of inhibitor. It is assumed that the 
predominantly hydrophobic nature of these compounds 65 
facilitated successful permeation of the cell membrane 
despite the phosphate. 
In summary, herein are disclosed the first rationally 
designed small-molecule inhibitors of STAT3 dimerization 
that disrupt STAT3-mediated cell proliferation pathways. 
Suitably substituted oxazole and thiazole scaffolds, derived 
from peptidomimetic leads, disrupted STAT3:STAT3-DNA-
binding activity in vitro at low micromolar concentrations, 
but showed low affinity to the unphosphorylated STAT3 
monomer. This might suggest that the present compounds 
preferentially bind with activated STAT3, a hypothesis which 
is further supported by the lack of activity against control 
cells (NIH-3T3); however, this remains to be verified. Lead 
agents showed potency and specific human cancer cell lines 
and negligible toxicity towards normal NIH-3T3 fibroblasts. 
The present studies highlight the widely acknowledged belief 
that STAT3 is a potent target for disruption by small-molecule 
inhibitors for novel anticancer drug development and that 
targeting of STAT3 will require yet a further level of investi-
gation. 
US 8,969,578 B2 
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TABLE2 
EC50 values for selected inhibitors against constitutively 
activated STAT3 containing cell lines NIH3 T3/vSrc, Pane-
l MDA-231 and non-activated STAT3 NIH3T3 cells. 
Compound Panc-1 MDA-231 NIH3T3 NIH3T3/ 
No. ECso(µM) EC50 (µM) EC50 (µM) vSrc 
10 >1000 180 >1000 120 
18 
-continued 
o~ ,/lN~O/. 
I 
H 
6. The compound of claim 1, wherein X is sulfur. 
14 >1000 >1000 
16 >1000 300 
19 10 >1000 
>1000 480 
>1000 145 
>1000 700 
7. The compound of claim 1, whereinX is sulfur, andR2 is 
10 an amide group selected from: 
Accordingly, in the drawings and specification there have 
been disclosed typical preferred embodiments of the inven-
tion and although specific terms may have been employed, the 15 
terms are used in a descriptive sense only and not for purposes 
of limitation. The invention has been described in consider-
able detail with specific reference to these illustrated embodi-
ments. It will be apparent, however, that various modifica-
tions and changes can be made within the spirit and scope of 20 
the invention as described in the foregoing specification and 
as defined in the appended claims. 
That which is claimed: 
1. A compound having a chemical structure according to 
the formula: 
u ~: 
Ho'/"oN *-< 
HO R1, 
wherein Xis oxygen or sulfur, R1 is a phenyl group or a 
naphthyl group, and R2 is an amide group, 
wherein the compound is not: 
25 
30 
35 
0 
HO....._// 
p 
HO/ \ 
0 
~­
r 40 
N 
H 
2. A pharmaceutically acceptable salt of the compound of 
claim 1. 
3. A pharmaceutically acceptable composition containing 
the compound of claim 1 or a salt thereof. 
45 
50 
4. The compound of claim 1, wherein X is oxygen. 
5. The compound of claim 1, wherein Xis oxygen, and R2 55 
is an amide group selected from: 
60 
and 
0 
,/lN 
I 65 
H 
0 
_.--lN 
I 
H 
o~ _.--lN~O/. 
I 
H 
and 
8. The compound of claim 1, wherein R 1 is a phenyl group. 
9. The compound of claim 1, wherein, R1 is a naphthyl 
group. 
10. The compound of claim 1, selected from: 
0 
II p 
HO/f "o 
HO 
/ 
N 
" H 
ObN 
f ' 
/ 
N 
" H 
SbN 
f ' 
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-continued -continued 
0 / HO-p~ HO/\ 0 0 N 
N \ 
" H 
s H 
10 cdN 0 II p 
Ho,...../""-o 
A HO 
15 
0 
HO'-// n p HO/\ 0 0 20 /' N 0 
\ 
0 H 0 dN HO-p~ HO/\ 0 , 25 
0 
N 
\ 
0 H dN 30 0 HO'-// n p HO/\ 0 0 /' N O 
\ 
35 s H 
0 dN HO-p~ 
HO/\ 40 
0 
0 
0 
N HO'- f/ 
\ p 
s H 45 HO/\ 0 dN 0 Q/,and N 0 \ 0 H o!JN 50 
b 
0 HO-p~ 
55 HO/\ 0 
HO'- /j 0 p 
0 HO/\ 0 
0 Q/ 
N N 0 
\ 60 \ 
0 H s H cdN cdN 
65 A 
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11. The compound of claim 1, selected from: 
~°'fN 
'-0 
and 
N 
\ 
H 
N 
\ 
H 
(1 /' ~o 
N 
\ 
H 
12. A compound having a chemical structure according to 
the formula: 
10 
15 
20 
25 
30 
35 
40 
60 
65 
22 
wherein R 1 is a phenyl group or a naphthyl group, and R 2 is 
an amide group. 
13. A pharmaceutically acceptable salt of the compound of 
claim 12. 
14.A pharmaceutically acceptable composition containing 
the compound of claim 12 or a salt thereof. 
15. The compound of claim 12, wherein R1 is a phenyl 
group. 
16. The compound of claim 12, wherein R2 is an amide 
group selected from: 
17. The compound of claim 12, selected from: 
f" ~ 
::::::,._ 
::::::,._ 
/ 
N 
" H 
SbN 
f" ~ 
::::::,._ 
US 8,969,578 B2 
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and 
19. A pharmaceutically acceptable salt of the compound of 
claim 18. 
20. A pharmaceutically acceptable composition containing 
20 the compound of claim 18 or a salt thereof. 
25 
21. The compound of claim 18, wherein R1 is a phenyl 
group. 
22. A compound having a chemical structure according to 
the formula: 
R2 0-/;c 0 ~ -:::::--II I #N 
N 
\ 
H 
HO 
35 
~ t 
=-
wherein Xis oxygen or sulfur, and R2 is an amide group. 
23. A pharmaceutically acceptable salt of the compound of 
40 
claim 22. 
24. A pharmaceutically acceptable composition containing 
the compound of claim 22 or a salt thereof. 
0 
HO...._// p 
HO/\ 0 
(1 /" ~o 45 25. The compound of claim 22, wherein Xis sulfur. 26. The compound of claim 22, wherein R2 is an amide 
group selected from: N 
\ 
H 
18. A compound having a chemical structure according to 
the formula: 
wherein R 1 is a phenyl group or a naphthyl group, and R2 is 
an amide group selected from: 
50 
55 
60 
65 
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27. The compound of claim 22, selected from: 
0 HO--p~ 
HO/\ 
0 
0 
0 (5N 
0 HO--p~ 
HO/\ 
0 ~ 
0 
s (5N 
N 
\ 
H 
N 
\ 
H 
/ 
N 
" H 
10 
15 
20 
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0 
HO...__ /j 
p 
HO/\ 0 
0 
HO...__ /j 
p 
HO/\ 0 
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-continued 
0 
0 
and 
0 
0--/ 0 
N 
\ 
H 
0--/ 0 
N 
\ 
H 
28. A compound having a chemical structure according to 
the formula: 
wherein Xis oxygen or sulfur, and R2 is an amide group 
selected from: 
, and 
29. A pharmaceutically acceptable salt of the compound of 
claim 28. 
30. The compound of claim 28, wherein Xis sulfur. 
31. A pharmaceutically acceptable composition containing 
the compound of claim 28 or a salt thereof. 
US 8,969,578 B2 
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32. The compound of claim 28, selected from: 
0 HO-p~ 
HO/\ 
0 f" , 5 
0 
N 
\ 
0 H o3N 
0 HO-p~ 
HO/\ 
f" 0 ~ 0 
:::::::,._ 
N 
---=:::: \ 
s H o3N 
0 
HO'-. /j 
p 
HO/\ 0 
0 Q/,and 
N 0 
\ 
0 H o3N 
A 
0 
HO'-.. /j 
p 
HO/\ 0 
0 ,Q,,, 
N 0 
\ 
s H o3N 
A 
33. A compound having a chemical structure according to 
the formula: 
R2 
0 ~ :::::::-
11 I ;JN 
HO 
f" ~, 
:::::::--
wherein R2 is an amide group. 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
28 
34. A pharmaceutically acceptable salt of the compound of 
claim 33. 
35. A pharmaceutically acceptable composition containing 
the compound of claim 33 or a salt thereof. 
36. The compound of claim 33, wherein R2 is an amide 
group selected from: 
0 
,/lN~ I , 
H 
, and 
0 
,/lN 
I 
H 
00 
,,,-lN ~ O/· 
I 
H 
37. The compound of claim 33, selected from: 
0 / 
N 
" H 
0 
II ob p Ho,......f 'o HO f" ~ 
:::::::--
0 
N 
\ 
H 
0 6N 
and 
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-continued 
0 0--/ HO, /j p 0 0 
HO/\ 0 N 
\ 
H 
0 
38. A compound having a chemical structure according to 
the formula: 
R2 
o~ II JN 
Ho/f'o # s 
HO 
~ 
:::::::,._ 
wherein R2 is an amide group. 
39. A pharmaceutically acceptable salt of the compound of 
claim 38. 
40. A pharmaceutically acceptable composition containing 
the compound of claim 38 or a salt thereof. 
41. The compound of claim 38, wherein R2 is an amide 
group selected from: 
and 
10 
15 
20 
25 
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42. The compound of claim 38, selected from: 
0 
II p 
Ho'/f '-..0 
HO 
0 HO--p~ 
HO/\ 
0 
:::::::,._ 
0 
~J:'N 
'-0 
and 
:::::::,._ 
N 
\ 
H 
* * * * * 
/ 
N 
' H 
A /. ~o 
N 
\ 
H 
